Vital signs and work of breathing assessment in the emergency department as predictor for acute respiratory failure in COVID-19 pneumonia

Coronavirus disease 2019 (COVID-19) with acute respiratory failure (ARF) has a high mortality rate. This study aimed to investigate the vital signs and work of breathing parameters in COVID-19 pneumonia patients to predict ARF. We predicted the risk of acute respiratory distress syndrome (ARDS) in COVID-19 patients within 72 hours of admission to the emergency department (ED) and determined cut-off values. We performed an observational prospective cohort study at the tertiary referral Persahabatan Hospital in Jakarta, Indonesia, from July to December 2020. The vital signs were as follows: of respiratory rate (RR), heart rate (HR), pulse oxygen saturation (SpO2), mean arterial pressure (MAP), and axillary body temperature. The work of breathing, which was indicated by nasal flaring and the contraction of the sternocleidomastoid and abdominal muscles, was assessed one hour after a triage examination. The ARF was monitored within 72 hours. The cut-off values of vital signs were determined using the Youden index. In total, 71 (13.65%) of the 520 patients had ARF within 72 hours of admission. The mean values of RR, HR, MAP and SpO2 in the ARF group were 26 breaths/minute, and 102 pulses/minute, at 100 and 92%, respectively. All ARF patients had nasal flaring, 86.4% had a contraction of the sternocleidomastoid, and 67.6%had a contraction of the abdominal muscle. The cut-off values for predicting ARF were as follows: RR >23 breaths/minute (sensitivity 83.1%; specificity 86%), SpO2 <93% (sensitivity 80.5%; specificity 75.2%), HR = 92 pulses/minute (sensitivity 71.8%; sensitivity 75.2%), and MAP = 93.5 (specificity 64.8%; sensitivity 60.4%). Our results indicate that vital signs and work of breathing within the first hour in the emergency department can predict ARF in COVID-19 pneumonia patients within 72 hours.

Acute respiratory failure; COVID-19; Pneumonia; Vital signs; Work of breathing

[1] Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. The Lancet. 2021; 398: 622–637.

[2] Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia. 2021; 13: 14.

[3] Elhidsi M, Fachrucha F, Irawan RY. N-Acetylcysteine for COVID-19: a potential adjuvant therapy. Journal of Health Sciences. 2021; 11: 1–6.

[4] Sankey CB, McAvay G, Siner JM, Barsky CL, Chaudhry SI. “Deterioration to door time”: an exploratory analysis of delays in escalation of care for hospitalized patients. Journal of General Internal Medicine. 2016; 31: 895–900.

[5] Yi P, Yang X, Ding C, Chen Y, Xu K, Ni Q, et al. Risk factors and clinical features of deterioration in COVID-19 patients in Zhejiang, China: a single-centre, retrospective study. BMC Infectious Diseases. 2020; 20: 943.

[6] Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315: 788–800.

[7] Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, et al. COVID-19 mortality and its predictors in the elderly: a systematic review. Health Science Reports. 2022; 5: e657.

[8] Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Critical Care. 2020; 24: 516.

[9] Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. 2020; 395: 1763–1770.

[10] Montrief T, Ramzy M, Long B, Gottlieb M, Hercz D. COVID-19 respiratory support in the emergency department setting. The American Journal of Emergency Medicine. 2020; 38: 2160–2168.

[11] Bellani G, Pham T, Laffey JG. Missed or delayed diagnosis of ARDS: a common and serious problem. Intensive Care Medicine. 2020; 46: 1180–1183.

[12] Kellett J, Sebat F. Make vital signs great again—a call for action. European Journal of Internal Medicine. 2017; 45: 13–19.

[13] Gazmuri RJ, Apigo M, Fanapour P, Nadeem A. Abstract 108: work of breathing scale to assess need of intubation in Covid-19 pneumonia. Circulation. 2020; 142: A108.

[14] Barrett NA, Hart N, Camporota L. Assessment of work of breathing in patients with acute exacerbations of chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2019; 16: 418–428.

[15] Leuvan CHV, Mitchell I. Missed opportunities? An observational study of vital sign measurements. Critical Care and Resuscitation. 2008; 10: 111–115.

[16] Chua WL, Mackey S, Ng EKC, Liaw SY. Front line nurses’ experiences with deteriorating ward patients: a qualitative study. International Nursing Review. 2013; 60: 501–509.

[17] Bain W, Yang H, Shah FA, Suber T, Drohan C, Al-Yousif N, et al. COVID-19 versus non-COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes. Annals of the American Thoracic Society. 2021; 18: 1202–1210.

[18] Zhao X, Xu X, Yin H, Hu Q, Xiong T, Tang Y, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei province, China: a retrospective study. BMC Infectious Diseases. 2020; 20: 311.

[19] World Health Organization. Therapeutics and COVID-19: living guideline. 2022. Available at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2022.4 (Accessed: 04 September 2022).

[20] Elhidsi M, Rasmin M, Prasenohadi. In-hospital mortality of pulmonary tuberculosis with acute respiratory failure and related clinical risk factors. Journal of Clinical Tuberculosis and other Mycobacterial Diseases. 2021; 23: 100236.

[21] Rasmin M, Elhidsi M, Prasenohadi, Putra Yahya WS, Sutanto YS, Setijadi AR, et al. Underlying diseases and in-hospital mortality of acute respiratory failure patients: Indonesian prospective cohort study. Journal of Natural Science, Biology and Medicine. 2021; 12: 22–26.

[22] Rasmin M, Elhidsi M, Yahya WS. Characteristics and outcome of acute respiratory failure patients: a cross-sectional study from the national referral hospital for respiratory diseases. Pneumologia. 2018; 67:77–81.

[23] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599–3726.

[24] Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International. 2021; 99: S1–S87.

[25] DeMers D, Wachs D. Physiology, Mean Arterial Pressure. StatPearls. StatPearls Publishing: Treasure Island (FL). 2023.

[26] Drummond GB, Fischer D, Arvind DK. Current clinical methods of measurement of respiratory rate give imprecise values. ERJ Open Research. 2020; 6: 00023–02020.

[27] American Heart Association. All about heart rate (pulse). 2022. Available at: https://www.heart.org/en/health-topics/high-blood-pressure/the-facts-about-high-blood-pressure/all-about-heart-rate-pulse (Accessed: 04 September 2022).

[28] Boyer J, Eckmann J, Strohmayer K, Koele W, Federspiel M, Schenk M, et al. Investigation of non-invasive continuous body temperature measurements in a clinical setting using an adhesive axillary thermometer (SteadyTemp®). Frontiers in Digital Health. 2021; 3: 794274.

[29] Apigo M, Schechtman J, Dhliwayo N, Al Tameemi M, Gazmuri RJ. Development of a work of breathing scale and monitoring need of intubation in COVID-19 pneumonia. Critical Care. 2020; 24: 477.

[30] Chen SL, Feng HY, Xu H, Huang SS, Sun JF, Zhou L, et al. Patterns of deterioration in moderate patients with COVID-19 from Jan 2020 to Mar 2020: a multi-center, retrospective cohort study in China. Frontiers in Medicine. 2020; 7: 567296.

[31] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395: 497–506.

[32] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus—infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061–1069.

[33] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020; 395: 1054–1062.

[34] Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Critical Care. 2020; 24: 198.

[35] Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA Internal Medicine. 2020; 180: 1152–1154.

[36] Caillon A, Zhao K, Klein KO, Greenwood CMT, Lu Z, Paradis P, et al. High systolic blood pressure at hospital admission is an important risk factor in models predicting outcome of COVID-19 Patients. American Journal of Hypertension. 2021; 34: 282–290.

[37] Lee JY, Kim HA, Huh K, Hyun M, Rhee JY, Jang S, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. Journal of Korean Medical Science. 2020; 35: e223.

[38] Trecarichi EM, Mazzitelli M, Serapide F, Pelle MC, Tassone B, Arrighi E, et al. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Scientific Reports. 2020; 10: 20834.

[39] Ramos-Rincon J, Buonaiuto V, Ricci M, Martín-Carmona J, Paredes-Ruíz D, Calderón-Moreno M, et al. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. The Journals of Gerontology. 2021; 76: e28–e37.

[40] Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D’Agnano V, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clinical and Experimental Research. 2020; 32: 1599–1608.

[41] Youssef Ali Amer A, Wouters F, Vranken J, Dreesen P, de Korte-de Boer D, van Rosmalen F, et al. Vital signs prediction for COVID-19 patients in ICU. Sensors. 2021; 21: 8131.

[42] Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Research and Clinical Practice. 2020; 167: 108382.

[43] Sands KE, Wenzel RP, McLean LE, Korwek KM, Roach JD, Miller KM, et al. Patient characteristics and admitting vital signs associated with coronavirus disease 2019 (COVID-19)—related mortality among patients admitted with noncritical illness. Infection Control & Hospital Epidemiology. 2021; 42: 399–405.

[44] Elhidsi M, Kusumoputri Buwono DA, Musridharta E, Soehardiman D, Prasenohadi P. Non-invasive ventilation in neuromuscular disease with acute respiratory failure: a narrative review. Romanian Journal of Neurology. 2022; 21: 219–224.

[45] Marjanovic N, Mimoz O, Guenezan J. An easy and accurate respiratory rate monitor is necessary. Journal of Clinical Monitoring and Computing. 2020; 34: 221–222.

[46] Rolfe S. The importance of respiratory rate monitoring. British Journal of Nursing. 2019; 28: 504–508.

[47] Carrara M, Ferrario M, Bollen Pinto B, Herpain A. The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review. Annals of Intensive Care. 2021; 11: 80.

[48] Chatterjee NA, Jensen PN, Harris AW, Nguyen DD, Huang HD, Cheng RK, et al. Admission respiratory status predicts mortality in COVID-19. Influenza and other Respiratory Viruses. 2021; 15: 569–572.

[49] Gibson PG, Qin L, Puah SH. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. The Medical Journal of Australia. 2020; 213: 54–56.e1.

[50] Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of ‘happy’ hypoxemia in COVID-19. Respiratory Research. 2020; 21: 198.

[51] Tharakan S, Nomoto K, Miyashita S, Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. Critical Care. 2020; 24: 298.

[52] World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatria i Medycyna Rodzinna. 2020; 16: 9–26.

[53] Elhidsi M, Rasmin M, Prasenohadi, Aniwidyaningsih W, Desianti GA, Alatas MF, et al. Rational supplemental oxygen therapy in COVID-19. Sahel Medical Journal. 2020; 23: 201–205.

[54] Barrot L, Asfar P, Mauny F, Winiszewski H, Montini F, Badie J, et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. The New England Journal of Medicine. 2020; 382: 999–1008.

[55] Joshi LR. Principles, utility and limitations of pulse oximetry in management of COVID-19. Journal of Lumbini Medical College. 2020; 8: 105–110.

[56] Ikram AS, Pillay S. Admission vital signs as predictors of COVID-19 mortality: a retrospective cross-sectional study. BMC Emergency Medicine. 2022; 22: 68.

[57] Akhavan AR, Habboushe JP, Gulati R, Iheagwara O, Watterson J, Thomas S, et al. Risk stratification of COVID-19 patients using ambulatory oxygen saturation in the emergency department. The Western Journal of Emergency Medicine. 2020; 21: 5–14.

[58] Nematswerani N, Collie S, Chen T, Cohen M, Champion J, Feldman C, et al. The impact of routine pulse oximetry use on outcomes in COVID-19-infected patients at increased risk of severe disease: a retrospective cohort analysis. South African Medical Journal. 2021; 111: 950–956.